How It Works | PrecisoCare®
Home How It Works
Clinical Workflow
Order to Follow-Up

From order to clinical action — every step governed and traceable

PRECISOCARE® manages the full genomic testing lifecycle — enrollment, ordering, sample tracking, lab coordination, results delivery, and longitudinal follow-up — within a single governed platform designed for institutional deployment.

HIPAA-aligned Full audit trail CLIA / CAP Labs FHIR / HL7
6
Governed workflow stages from enrollment to follow-up
360°
Full chain-of-custody visibility from sample collection to report
PHIN®
Network-enabled clinical coordination across provider touchpoints
Audit
Every action logged, traceable, and compliant
The Workflow

Six governed stages — no gaps, no manual workarounds

Every stage of the genomic testing workflow is structured, logged, and actionable within PRECISOCARE®. Providers interact with a single operational platform rather than coordinating across disconnected systems.

01

Patient Enrollment & Consent

Structured enrollment begins with eligibility screening against program-specific criteria. Digital consent workflows capture patient or guardian authorization with document storage and audit logging. Pre-test education materials are delivered at point of consent, ensuring patients understand what whole-genome sequencing involves, what it can and cannot identify, and how results will be used.

Clinical governance note

All consent workflows are program-specific and configurable to institutional requirements. Consent records are versioned, timestamped, and retrievable for compliance review. Pre-test genetic counseling referral triggers are built into enrollment for high-complexity cases.

02

Test Ordering

Providers place orders through PRECISOCARE® with program-guided test selection and clinical indication documentation. Orders route automatically based on program logic — Newborn, Pediatric, Adult, or Senior — with appropriate specimen requirements, ICD code guidance, and lab routing pre-configured. Order confirmation, lab acknowledgement, and specimen receipt are all captured and visible in the provider dashboard.

🔬
Program-guided ordering Test selection constrained to clinically appropriate options per program and indication
📋
ICD code guidance Clinical indication documentation built into ordering flow — supports billing and audit
03

Sample Collection & Chain-of-Custody

Specimen collection follows program-specific protocols with step-by-step guidance for clinical staff. Sample identity, collection timestamp, collector identity, and handling conditions are documented at collection. Once shipped, PRECISOCARE® provides chain-of-custody tracking from collection point through laboratory receipt — with alerts for delays, temperature deviations, or specimen quality concerns.

Why this matters

Genomic testing on misidentified or compromised specimens generates results that can lead to incorrect clinical decisions. PRECISOCARE® chain-of-custody controls eliminate this risk category at the system level, not through manual process.

04

Laboratory Processing (CLIA/CAP)

All genomic testing is processed through CLIA-certified and CAP-accredited laboratories. Whole-genome sequencing delivers the highest resolution diagnostic data available — covering single nucleotide variants (SNVs), copy number variants (CNVs), structural variants, indels, and mitochondrial variants in a single test. Laboratory turnaround time, QC status, and processing stage are visible within PRECISOCARE® throughout processing.

🏛️
CLIA-certified / CAP-accredited All testing meets federal CLIA certification and College of American Pathologists accreditation standards
🧬
WGS — full genomic coverage SNVs, CNVs, structural variants, indels, mitochondrial variants — all in a single test
05

Provider-Ready Reporting

Results are delivered as provider-ready reports formatted for clinical decision-making — not raw genomic data requiring specialist interpretation. Findings are classified by clinical significance (Pathogenic, Likely Pathogenic, Variant of Uncertain Significance, Benign), annotated with recommended clinical actions, and prioritized by urgency. PHIN®-enabled coordination routes critical findings for immediate provider notification.

Report design principle

Every report section is designed to answer one question: "What should I do next?" Variant classifications align to ACMG/AMP criteria. PGx results map to CPIC prescribing guidelines. The report is a clinical tool, not a data dump.

06

Longitudinal Follow-Up & Continuity

Genomic data is longitudinal by nature — a variant identified today remains clinically relevant as new evidence emerges, as family members are tested, or as the patient progresses through different health states. PRECISOCARE® maintains the patient's genomic record across programs, providers, and time — enabling reinterpretation as classifications update, cascade family testing coordination, and continuity across the care continuum.

♾️
Lifelong genomic record Test once — maintain and reinterpret across the patient's lifetime as evidence evolves
👨‍👩‍👧
Family cascade coordination Structured family testing workflows when hereditary conditions are identified
PHIN® Integration

Clinical coordination across every touchpoint

PHIN® (Predictiv Health Intelligence Network) is the coordination layer that connects PRECISOCARE® workflows to the broader clinical ecosystem — enabling intelligent routing of results, alerts, referrals, and follow-up actions.

🔔

Intelligent Alerting

Critical and urgent findings are routed immediately to the appropriate provider with alert logic that respects care team structure, role-based access controls, and escalation protocols.

↗️

Specialist Referral Routing

Results requiring specialist review — genetics, cardiology, oncology, neurology — trigger structured referral workflows with relevant clinical context pre-populated for the receiving provider.

📊

Population-Level Visibility

Program administrators and clinical leadership gain population-level dashboards — enrollment rates, results distribution, follow-up completion rates, and program compliance metrics.

Common Questions

Workflow & implementation FAQ

How long does the end-to-end process take from order to results?
Turnaround time varies by program and laboratory. Whole-genome sequencing typically requires 3–6 weeks from sample receipt to final report. Newborn NICU cases may be prioritized for rapid turnaround (days). PRECISOCARE® provides real-time status visibility throughout, so providers always know where their patient's sample stands in the pipeline.
How does PRECISOCARE® integrate with our existing EHR?
PRECISOCARE® supports FHIR and HL7 standards for EHR interoperability. Implementation includes an integration assessment to map data flows between your existing systems and PRECISOCARE®. Full EHR integration is configured during the implementation phase — providers do not need to operate a parallel system for routine workflows.
What happens when a result requires specialist follow-up?
PHIN® routes results requiring specialist review through structured referral workflows. The receiving specialist receives the relevant clinical context alongside the genomic result — not just a raw report. Genetic counselors are available for results requiring complex communication, reproductive counseling, or family cascade coordination.
Can patients access their own genomic results?
Patient access to genomic results is configured per institutional policy and program design. PRECISOCARE® supports patient portal delivery where appropriate. For programs involving sensitive variants (e.g., adult-onset neurological conditions, cognitive risk), results are typically delivered through a provider-mediated or genetic counseling-supported disclosure process.
How are variants of uncertain significance (VUS) handled?
VUS findings are reported with current classification and clinical context. PRECISOCARE® maintains VUS records for reclassification as evidence evolves — a key advantage of WGS over single-gene or panel testing. Providers and patients are notified when a previously reported VUS is reclassified to pathogenic or benign based on new evidence.

See the full workflow in your clinical environment

Implementation planning begins with a workflow assessment. Request access to connect with the PRECISO team and map the platform to your existing clinical operations.